GlassScriptPhysician profile
Steven M Stoll
NPI 1518192004
$20,418.02
in general payments reported to CMS, 2019-2025
74 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,846 · 2021: $6,506 · 2022: $2,806 · 2023: $2,483 · 2024: $2,842 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,137.30 | 2019-2025 | Yeztugo |
| Abbvie INC. | $2,834.22 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,490.28 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $995.65 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $887.51 | 2019-2025 | Trintellix, Cuvitru |
| Allergan, INC. | $639.04 | 2019-2020 | |
| Viiv Healthcare Company | $582.80 | 2022-2025 | Apretude |
| Lilly USA, LLC | $531.47 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Astrazeneca Pharmaceuticals LP | $497.16 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $379.74 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $374.41 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Neos Therapeutics, LP | $289.80 | 2019-2023 | Adzenys Xr-Odt |
| Daiichi Sankyo INC. | $273.76 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.46 | 2019-2025 | Xifaxan |
| Amgen INC. | $226.59 | 2021-2023 | Otezla, Repatha |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Stoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.